Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Cathinone or Dissociative or TCA

Use the filters below to narrow your results.

generic:
brand:
None (32) · Anafranil (1) · DXM (1) · DXO (1) · Ludiomil (1) · Norpramin (1) · Spravato (1) · Surmontil (1) · Tofranil (1) · Vivactil (1)
classes: (Click arrow to add another value)
mechanism:
None (1) · Active metabolite of DXM; NMDA antagonist (1) · Cathinone analogue; monoamine reuptake inhibitor (2) · Contains salvinorin A (1) · Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) · Kappa-opioid receptor agonist (1) · Monoamine releasing agent (4) · Monoamine releasing agent; active ingredient in khat (1) · NMDA antagonist (3) · NMDA antagonist; endogenous opioid releaser (1) · NMDA antagonist; fluorinated ketamine analogue (1) · NMDA antagonist; kappa-opioid agonist (1) · NMDA antagonist; ketamine analogue (1) · NMDA antagonist; more stimulating than PCP (1) · NMDA antagonist; opioid agonist (1) · NMDA antagonist; potent opioid agonist (1) · NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) · NMDA antagonist; sigma receptor agonist (2) · NMDA antagonist; sigma receptor agonist; dopaminergic (1) · NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) · Norepinephrine and dopamine releasing agent (1) · Norepinephrine/dopamine releasing agent (1) · Norepinephrine/dopamine reuptake inhibitor (1) · Potent serotonin reuptake inhibitor; also NRI (1) · Selective norepinephrine reuptake inhibitor (2) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin releasing agent; monoamine reuptake inhibitor (1) · Serotonin/norepinephrine/dopamine releasing agent (3) · Weak SRI; primarily H1/D2/alpha antagonist (1)
uses:
None (40) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)
starting dose:
None (40) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
preparations:
None (40) · 28 mg/device (each dose uses 2 devices) (1)
fda max:
None (40) · 84 mg per session (1)
routes:
None (40) · Intranasal (under direct medical supervision) (1)
onset:
None (40) · Within hours of first administration (1)
duration:
None (40) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)
halflife:
None (40) · ~7-12 hours (1)
bioavailability:
None (40) · ~48% intranasal (1)
pregnancy:
None (40) · Avoid; may cause fetal harm (1)
legal:
None (40) · Rx, Schedule III (US). REMS program required. (1)

Showing below up to 41 results in range #1 to #41.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"